Researchers at the Icahn School of Medicine at Mount Sinai have uncovered critical new details regarding how APOE4, the strongest known genetic risk factor for Alzheimer’s disease, actively contributes to brain damage. In two landmark studies published in the journals Cell and Cell Stem Cell, the scientific team demonstrated that the gene is capable of directly damaging the brain’s delicate blood vessels and encouraging the accumulation of abnormal, toxic proteins associated with widespread neurodegenerative diseases.
Crucially, the new findings point to biological processes that may be entirely reversible. Furthermore, the research highlights an innovative human brain tissue platform derived from stem cells that could dramatically accelerate the global search for effective treatments.
Alzheimer’s disease is a devastating condition that gradually erodes memory, cognitive thinking, and behavioral patterns, currently affecting more than 7 million older adults in the United States alone. For many years, medical researchers have been well aware that the blood vessels within the brain progressively deteriorate as Alzheimer’s advances, a phenomenon particularly pronounced in individuals who carry the APOE4 genetic variant. However, what has remained elusive is the exact mechanism behind this deterioration and whether vascular damage acts as a direct driver of the disease. Because of this historical uncertainty, vascular damage in the brain has frequently been categorized merely as a downstream consequence or side effect of Alzheimer’s rather than a primary catalyst actively pushing the pathology forward.
Mapping How APOE4 Damages Brain Blood Vessels
To untangle this complex relationship for the study published in Cell on September 24, Mount Sinai scientists integrated existing datasets to construct a comprehensive single-cell transcriptomic atlas mapping the blood vessels of the human brain. This newly generated map revealed intricate patterns of gene activity across the diverse array of individual cells that construct and support the brain’s expansive vascular network, providing researchers with an unprecedented high-resolution tool to examine how APOE4 drives vascular degeneration.
Through this detailed mapping, the research team discovered that APOE4 fundamentally alters the biological behavior of pericytes. Under normal physiological conditions, these specialized cells play a vital role in stabilizing small blood vessels and maintaining the integrity of the protective blood-brain barrier. However, in the presence of the APOE4 gene, these pericytes undergo a pathological transformation, converting into myofibroblast-like cells that actively manufacture scar tissue.
This cellular metamorphosis promotes severe vascular fibrosis and accelerates the buildup of amyloid proteins tightly clustered around the brain’s blood vessels. These structural and biochemical changes severely compromise normal blood flow, restricting the delivery of vital nutrients and oxygen while creating a microenvironment that strongly encourages progressive neurodegeneration.
Significantly, the research team also uncovered compelling evidence suggesting that this damaging process is not permanent. By blocking TGF-beta signaling—a molecular pathway that heavily influences communication between cells and drives tissue remodeling—the scientists successfully restored pericyte coverage while simultaneously reducing both fibrosis and amyloid accumulation around the blood vessels. The researchers were able to successfully replicate these remarkable results in aged mice carrying the APOE4 gene, demonstrating definitively that the vascular degeneration driven by APOE4 can be therapeutically reversed.
"Damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible," said corresponding author Joel W. Blanchard, PhD, Associate Professor of Neuroscience, and Stem Cell Biology and Regenerative Medicine, at the Icahn School of Medicine at Mount Sinai. "These findings reveal new therapeutic targets for preserving vascular function and limiting amyloid accumulation."
Echoing this perspective, first author Braxton R. Schuldt, an MD/PhD candidate in Neuroscience and a researcher in the Blanchard Laboratory, noted the implications for prevention and treatment. "We show that APOE4 converts blood-vessel support cells into scar-producing cells, causing amyloid or abnormal protein buildup to accumulate around the brain’s vessels. Through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain’s circulation in people at high genetic risk for Alzheimer’s disease."
Human miBrains Reveal Disease Mechanisms
A foundational element enabling this extensive research was the use of miBrains, which are sophisticated, three-dimensional human brain tissue models developed by the Mount Sinai team from induced pluripotent stem cells. This advanced model faithfully reproduces critical structural and functional features of human brain tissue, including a complex, interconnected network of blood vessels.
The Blanchard laboratory successfully combined findings gathered from miBrains with preclinical animal models, postmortem human brain tissue samples, and detailed transcriptomic data. Each distinct experimental approach served to cross-examine, confirm, and expand upon observations made across the others, creating a robust framework of validation.
By bringing these advanced systems together, the scientists were able to recreate early events that occur long before the appearance of the severe vascular abnormalities typically observed in postmortem human brain tissue. This capability allowed them to pinpoint the exact molecular mechanisms driving those changes and rapidly test potential therapeutic interventions.
APOE4 May Also Disrupt the Brain’s Protein Cleanup
In the companion study published in Cell Stem Cell, the researchers utilized the miBrain platform to investigate another profound consequence of APOE4: its specific role in the abnormal accumulation of proteins deeply linked to neurodegenerative disorders.
The pathological buildup of abnormal proteins stands as a defining hallmark of devastating conditions such as both Alzheimer’s and Parkinson’s disease. Nevertheless, investigating the precise mechanisms by which these toxic deposits form inside a living human brain has historically presented immense technical challenges. The miBrain system provides scientists with a novel window to observe these intricate biological processes unfolding within complex, human-like brain tissue under tightly controlled laboratory conditions.
miBrains incorporate all of the major cell types normally present within the human brain, encompassing functional neurons, supporting glial cells, myelin-producing cells, and the specialized cells that construct blood vessels. Mirroring the pathology seen in human patients, miBrains engineered to carry APOE4 developed significantly higher concentrations of abnormal alpha-synuclein. This specific protein is most strongly associated with Lewy body dementia and Parkinson’s disease.
Although alpha-synuclein holds immense clinical importance in the study of neurodegenerative disorders, the specific cellular pathways and triggers that cause it to accumulate inside cells have remained poorly understood by the scientific community.
Cholesterol Buildup Disrupts Cellular Waste Removal
Through meticulous experimentation, the research team discovered that APOE4 triggers a pathological accumulation of cholesterol specifically inside astrocytes, which are essential support cells that perform a wide array of critical functions necessary for maintaining overall brain health.
This localized excess of cholesterol directly interfered with the normal functioning of the astrocytes’ lysosomal waste-disposal system. Consequently, the cells suffered a sharp decline in their efficiency at breaking down and clearing away alpha-synuclein. Rather than being safely degraded and removed, the protein began to accumulate internally and eventually spread outward to neighboring neurons, where it contributed directly to the formation of harmful, toxic deposits.
These critical findings strongly suggest that cholesterol metabolism occurring inside astrocytes, alongside overall lysosomal clearance function, could represent highly promising new treatment targets for combating both Alzheimer’s and Parkinson’s disease.
By leveraging the unique capabilities of the miBrain platform, the researchers successfully traced the complete chain of events within complex human brain tissue. Their experiments definitively linked APOE4 to lipid buildup in astrocytes, impaired clearance of alpha-synuclein, and the subsequent generation of toxic protein deposits. The results highlight both lipid metabolism and cellular waste management systems as primary avenues for future therapeutic drug development in neurodegenerative medicine.
A Platform for Testing Personalized Treatments
Another distinct operational advantage offered by the miBrain system is the capability to preserve the manufactured tissue for future experimental use, ensuring consistency across long-term investigations.
"A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved," said Louise Mesentier-Louro, PhD, Assistant Professor of Neuroscience, and Stem Cell Biology and Regenerative Medicine, at the Icahn School of Medicine at Mount Sinai, and first author of the Cell Stem Cell study. "This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation."
Building on this success, Mount Sinai researchers are actively working on developing miBrains derived directly from individual patients. This personalized approach could eventually empower scientists to investigate the subtle ways in which neurodegenerative diseases manifest differently from person to person, while also predicting how individual patients might respond to specific pharmacological treatments.
"At Mount Sinai we are creating and cryopreserving miBrains from patients," Dr. Blanchard added. "This will enable personalized studies into how neurodegenerative disease develops and how individuals may respond to therapies. By enabling potential therapies to be tested earlier and more efficiently, the miBrain platform could help bridge the gap between laboratory discoveries and treatments for a broad range of disorders."
The research examining vascular degeneration in the brain received financial support from the National Aeronautics and Space Administration, the National Institute on Aging at the National Institutes of Health, The SWT Foundation, and the CureAlz Fund. Meanwhile, the study investigating abnormal protein buildup in the brain was supported by the National Aeronautics and Space Administration, Aligning Science Across Parkinson’s through the Michael J. Fox Foundation for Parkinson’s Research, the National Institute of Neurological Disorders and Stroke, the National Institute on Aging at the National Institutes of Health, the CureAlz Fund, and The SWT Foundation.
